We are offering COVID-19 vaccines to current patients. Patients can schedule a vaccination through NYU Langone Health MyChart or the NYU Langone Health app. Learn more about the COVID-19 vaccine.

If you need help accessing our website, call 855-698-9991
Skip to main content
NYU Langone Provider

Jennifer Wu, MD

NYU Langone Provider
  • Specialties: Medical Oncology, Hematology
  • Language: English

I was first drawn to medicine because I wanted to help people. I chose hematology and oncology because they are rapidly evolving fields—through their advances, I can treat people using the newest therapies. More importantly, I can care for people by forging meaningful relationships with them.

I treat each patient as a partner, and together, we work toward a common goal. Communication with my patients and their caregivers is essential to providing the best care. I also prioritize providing my patients with access to clinical trials.

At Perlmutter Cancer Center, my colleagues and I approach cancer treatment as a collaboration between specialties. We offer patients the most current clinical trials and we strive to provide as much support as possible for patients and families during such a difficult time.

My clinical and research interest is gastrointestinal cancers, with a focus on liver and biliary cancer, pancreatic cancer, and gastric cancer. Currently, I am studying whether radiation therapy in combination with immunotherapy is an effective treatment for pancreatic cancer.


Conditions and Treatments

Conditions
  • gastrointestinal cancer
  • colon cancer
  • rectal cancer
  • pancreatic cancer
  • esophageal cancer
  • stomach cancer
  • anal cancer
  • gallbladder cancer
  • biliary cancer
  • liver cancer
  • colorectal cancer
  • abdominal tumor

Positions
Board Certifications
  • American Board of Internal Medicine - Internal Medicine, 2003
Education and Training
  • Fellowship, NYU Medical Center, Hematology/Oncology, 2006
  • Fellowship, NYU Medical Center, Hematology/Oncology, 2004
  • MD from Albert Einstein College of Med, 2000

Is this your profile?

Edit profile

This provider accepts the following insurance plans.

This list of insurances changes regularly, and insurance plans listed may not be accepted at all office locations for this provider. Before your appointment, please confirm with your insurance company that this provider accepts your insurance.

  • A Phase Ib/II Multicenter Open-label Modular Dose-Finding and Dose Expansion Study to Explore the Safety Tolerability and Anti-tumor Activity of Trastuzumab Deruxtecan (DS-8201a T-DXd) in Combination with other Anti-cancer Agents in Patients with Metastatic HER2-positive Breast Cancer (DESTINY-Breast07)

    Learn More
  • Randomized Phase II Trial of Topotecan plus M6620 (VX-970) vs. Topotecan alone in Patients with Relapsed Small-Cell Lung Cancer

    Learn More
  • A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)

    Learn More
View All Research Studies (26)

Read All Publications (30)